Juvenescence® is a biotech company that aims to extend human lifespan and improve overall health. Founded in 2016 and headquartered in Man (Isle of), the company has assembled a team of highly experienced drug developers, entrepreneurs, marketers, and investors with a track record of success in pharmaceutical drug development, synthetic biology, and tissue and cellular engineering.
The company is focused on developing therapies to modify aging and enhance healthy human lifespan. With a broad pipeline in development, Juvenescence® is committed to driving innovation in the field, with an emphasis on discovering and developing therapies to alter the aging process through prevention and regenerating damage to support healthy aging and increase health span.
Despite not having specific information on the last investment and investors, Juvenescence® has positioned itself as a promising player in the life sciences industry, addressing the challenges and opportunities associated with aging and longevity.
There is no investment information
No recent news or press coverage available for Juvenescence®.